Results 61 to 70 of about 7,269 (215)
Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.ABSTRACT Pituitary adenomas (PAs) are common intracranial tumours, and invasiveness in nonfunctioning invasive pituitary adenomas (NIPAs) predicts poor prognosis. The molecular mechanisms driving this phenotype remain unclear. This study explored the role of nuclear receptor subfamily 3 group C member 1 (NR3C1) in NIPA invasiveness and its regulation ...
Xiaoping Wang +6 more
wiley +1 more source
Endocrine Oncology, 2023 The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy as the first-line treatment, with surgical resection reserved for cases where there is DA failure due to resistance or intolerance.
Sunita M C De Sousa
doaj +1 more source
Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.Abstract The chemokine network in the microenvironment of pituitary neuroendocrine tumours (PitNETs) may modulate tumour biology, aggressiveness, and treatment responses. We aimed to study the role of various chemokines and chemokine receptors in defining PitNET phenotype and clinical outcomes.
Ana Luísa Silva +13 more
wiley +1 more source
Acromegaly: pathogenesis & treatment [PDF]
, 2019 Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core
Transnasal endoscopic surgery of the sellar region: study of the first 100 cases [PDF]
, 2003 An endoscopic endonasal transsphenoidal approach to the sella was performed in 100 consecutive patients, with a follow up from 3 to 55 months: 57 females and 43 males, age ranging from 14 and 70 years.
Gondim, Jackson +2 more
core +3 more sources
Transsphenoidal surgery for prolactinomas in male patients: a retrospective study
Asian Journal of Andrology, 2023 Male patients with prolactinomas usually present with typical hyperprolactinemia symptoms, including sexual dysfunction and infertility. However, clinical factors related to sexual dysfunction and surgical outcomes in these patients remain unclear.
Wei-Jie Su +8 more
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.Loss of INPP5A in PitNETs disrupts IP3 clearance and drives aberrant PI3K/Akt activation. PKA‐dependent phosphorylation stabilizes MBD2 via 14‐3‐3σ, sustaining transcriptional silencing of INPP5A. MBD2 inhibition sensitizes tumors to standard treatments and limits PitNET growth.
Qian Jiang +12 more
wiley +1 more source
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds [PDF]
, 2007 The antisecretory effects of somatostatin (SRIH) and its analogs are widely recognized and provide the basis for treatment of hormonal hypersecretion in patients with pituitary adenomas, especially in the settings of acromegaly.
Ambrosio, Maria Rosaria +3 more
core +1 more source
Equine Veterinary Education, Volume 38, Issue 3, Page e170-e179, March 2026.Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess +5 more
wiley +1 more source
Giant prolactinoma: case report and review of literature [PDF]
, 2013 “Invasive giant prolactinoma” is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms.
Bagher Larijani +3 more
core +2 more sources